Health Canada
www.hc-sc.gc.ca
Common menu bar links
Institutional links
About Health Canada
Access to Information Requests Completed - July 2011
This content was archived on June 24, 2013.
Archived Content
Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)
If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.
Acronyms and Descriptions
- AER
- Adverse Reaction Report (Adverse Event)
- DHA
- Drug Identification Number
- DIN
- Drug Identification Number
- FNIHB
- First Nations and Inuit Health Branch
- MECS
- Ministerial Executive Correspondence System
- NPN
- Natural Product Number
- PMRA
- Pest Management Regulatory Agency
- RAPB
- Regions and Programs Branch
Completed Requests
| Request # | Summary of Requests | Status of Completed Request | Number of Pages Disclosed |
|---|---|---|---|
| A-2009-00513 | Research and reports on potential hazards associated with children's toys. (Jan 1, 2009 to Jul 22, 2009). | Disclosed in part | 414 |
| A-2009-00570 | Information regarding the product Lumigan 0.01%. | Disclosed in part | 118 |
| A-2009-00617 | All documents relating to inspections made by Health Canada at Apotex Inc.'s. (Jan 1, 2005 to Aug 13, 2009). | Disclosed in part | 2,713 |
| A-2009-01172 | All recent exit notices following an inspection of good manufacturing practices to renew establishment licences for the wholesalers Kohl and Frish, Jean Coutu, Shoppers Drug Mart, Matrix and Amerisourcebergen. | Disclosed in part | 105 |
| A-2009-01202 | Information regarding the product O24, NPN 80000942. | Disclosed in part | 213 |
| A-2009-01243 | Information regarding the products Allegra 12 hour, Allegra 24 hour (120 mg) and Allegra-D, DINs 02231462, 02242819 and 02239853 by Sanofi-Aventis Canada Inc. | Disclosed in part | 756 |
| A-2009-01247 | Information regarding the product Novo-Salbutamol HFA (salbutamol sulfate). | Disclosed in part | 514 |
| A-2009-01248 | Information regarding the product Novo-Salbutamol HFA (salbutamol sulfate). | Disclosed in part | 514 |
| A-2009-01292 | Information regarding the product Allegra-D, DIN 02239853 by Sanofi-Aventis Canada Inc. | Disclosed in part | 784 |
| A-2009-01421 | Information regarding the product Newco Rub Ease, NPN 80007845 by NewCo Enterprises Inc. | Disclosed in part | 170 |
| A-2010-00032 | All documents that explain and outline the 2004 mediated settlement reached between the Minister of Health and the Apehtaw Kosisan Métis Child and Family Support Society. | Disclosed in part | 14 |
| A-2010-00123 | Report to Assistant Deputy Ministers of RAPB and FNIHB on Audit/Investigation for Poplar Hill Nursing Station + Financial irregularities regarding travel invoices. | All exempted | 0 |
| A-2010-00268 | All documents and information explaining why paragraph 10(c) of Part 1 of Schedule 1 was added to the Hazardous Products Act. | Disclosed in part | 25 |
| A-2010-00778 | Information regarding the products NOVO-CHOLAMINE and NOVO-CHOLAMINE LIGHT, DINs 02139189 and 02139197 by Novopharm Limited. | Disclosed in part | 156 |
| A-2010-00851 | Information regarding the product Rolaids Antacid Regular Strength, NPN 02239904 by McNeil Consumer Healthcare. | Disclosed in part | 71 |
| A-2010-00870 | Information regarding the product Alvesco, DINs 02285606 and 02285614 by Nycomed Canada Inc. | Disclosed in part | 1,387 |
| A-2010-00871 | Information regarding the product Oxeze, DINs 02237224 and 02237225 by Astrozeneca Inc. | Disclosed in part | 880 |
| A-2010-00974 | All the studies that have been generated from January 1, 2009 to December 7, 2010 regarding the department's need to survey tap water and water treatment facilities. | All disclosed | 1,634 |
| A-2010-01012 | List of all Briefing notes prepared for the Health Minister between Sep 1, 2010 and Jan 5, 2011. | Disclosed in part | 168 |
| A-2010-01042 | All documents of Paul Glover prepared for Colin Carrie and Minister Aglukkaq related to Imperial Tobacco, JTI-MacDonald, Rothman's Benson and Hedges and other tobacco industry stakeholders. (Sep 01, 2009 to Dec 17, 2010). | Disclosed in part | 145 |
| A-2010-01047 | All documents related to August 2010 teleconferences between Health Canada authorities and their provincial counterparts on tobacco, tobacco products, labelling, toll free quit line. | Disclosed in part | 51 |
| A-2010-01178 | Information regarding the product Crest Shield Protect; Crest Pro-Health Clinical Gum Protection, NPN 80012433. | Disclosed in part | 213 |
| A-2010-01200 | The initial Cash Flow Statement submitted by Canada Health Infoway Inc - for 2007-2008 fiscal year. | All disclosed | 2 |
| A-2010-01210 | All agendas and minutes with supporting documents of Healthy Foods Working Groups. (Sep 1, 2010 to Jan 31, 2011). | Disclosed in part | 41 |
| A-2010-01211 | All agendas and minutes with supporting documents of Healthy Foods Working Groups. (Jan 1, 2010 to Aug 31, 2010). | Disclosed in part | 34 |
| A-2010-01281 | Information regarding the product Fosamax by Merck Frosst. | Disclosed in part | 921 |
| A-2010-01296 | All documents pertaining to caffeinated energy drinks. (Jan 1, 2006 to Feb 16, 2011). | Disclosed in part | 2,549 |
| A-2010-01321 | All information correspondence between Health Canada and Little Red River Cree Nation. (Jan 1, 2010 to Dec 1, 2010). | Disclosed in part | 979 |
| A-2010-01327 | All documents regarding the analysis of additives or ingredients that mention sucrose saccharin or aspartame for all tobacco products. (Jan 1 2000 to Feb 21, 2011). | Disclosed in part | 155 |
| A-2010-01348 | Copies of any memorandum or emails from Health Canada representatives with respect to any adverse reactions or any adverse reaction reports in connection with GABAPENTIN. (Jan 1, 2009 to Feb 23, 2011). | Disclosed in part | 57 |
| A-2010-01413 | All information related to a notification from Health Canada to the company Martek Biosciences that said company may add 20mg of DHA from algal oil to foods intended for children 2 years of age and under. | Disclosed in part | 393 |
| A-2010-01434 | Information regarding the product Oestrilin Crème Vaginale 1mg, DIN 00006149. | All disclosed | 13 |
| A-2010-01440 | The data collected since the inception of the PMRA's Pesticide Sales Registry pertaining to the sales of pesticides at the regional, provincial and national level. | Disclosed in part | 1,435 |
| A-2010-01478 | A study to determine if increasing PAH concentrations in soil increases dose in a Juvenile Swine Model prepared by the University Of Saskatchewan Department Of Soil Science. | All disclosed | 648 |
| A-2010-01523 | AERs for the product Tecta (pantoprazole magnesium). Report numbers: 000353719, 000356176 and 000358511. | Disclosed in part | 6 |
| A-2010-01599 | Information regarding medicinal marihuana production and inspections within the Province of British Columbia for the communities of Kelowna, and Central Okanagan Regional District. | Disclosed in part | 1 |
| A-2011-00008 | All documents regarding vitamin enriched waters and health claims. (Jul 1, 2008 to Feb 20, 2009). | Disclosed in part | 261 |
| A-2011-00013 | Information regarding the product Goji Berry Standarized, NPN 80017575. | All disclosed | 94 |
| A-2011-00084 | Information regarding the product SP Green Food, NPN 80023971 by Standard Process Inc. | Disclosed in part | 147 |
| A-2011-00134 | AER for the product Clopixol. Report number: 000355605. | Disclosed in part | 9 |
| A-2011-00135 | Copy of the Cosmetic Notification Form 92633-0 for Sally Hansen Professional Kwik Off product. | Disclosed in part | 1 |
| A-2011-00138 | Copies of the classification rationale, point rating and job description for the position titled Case Management Specialist, PM5. Posted on the Public Service Staffing site on April 13, 2011, selection process 11-NHW-NX-INA-008. | All disclosed | 18 |
| A-2011-00139 | Reports which contain signal assessment information on atypical subtrochanteric & diaphyseal femoral fractures risk with bisphosphonates. Review report numbers: 11-100728-420 - 2011-01-12 11-100759-814 - 2011-01-12 11-100761-358 - 2011-01-12 |
All disclosed | 163 |
| A-2011-00143 | The complete list of NPNs issued to date (May 2, 2011). | All disclosed | 556 |
| A-2011-00145 | Health Canada Review Reports for Bonefos® regarding signal assessment for atypical subtrochanteric & diaphyseal femoral fractures or inflammatory ocular events. Review report numbers: 11-100728-420 - 2011-01-12 11-100759-814 - 2011-01-12 11-100761-358 - 2011-01-12 |
Disclosed in part | 217 |
| A-2011-00209 | Copies of all transitions documents prepared on the NDP (New Democratic Party) platform and policy. (Mar 25, 2011 to May 12, 2011). | Disclosed in part | 41 |
| A-2011-00215 | A list of all completed Access to Information requests. (Jan 1, 2011 to May 17, 2011). | Disclosed in part | 148 |
| A-2011-00220 | Information regarding the product HYCODAN Tablets and HYCODAN Syrup, DINs 01916599 and 01916580. | Disclosed in part | 6 |
| A-2011-00245 | Complete list of all Question Period notes, memoranda that were created by or sent to the Minister of Health. (Apr 20, 2011, to May 16, 2011). | All disclosed | 6 |
| A-2011-00259 | Information related to the patent hold regarding the product pms-pantoprazole 20mg 40mg tablets prior to June 3, 2008. | Disclosed in part | 2 |
| A-2011-00261 | Information related to the patent hold regarding the product Sandoz pantoprazole 20mg 40mg tablets prior to June 3, 2008. | Disclosed in part | 2 |
| A-2011-00265 | Previously released request A-2007-00179: Information regarding the product ACTONEL. | Disclosed in part | 324 |
| A-2011-00287 | AERs for the product Epival. Report numbers: 000352673 and 000355605. | Disclosed in part | 10 |
| A-2011-00291 | Information regarding the product Lakota Joint Care Roll-On; Lakota Muscle Pain Roll-On, NPN 80003444 by HPI Health Products Inc. - Lakota. | Disclosed in part | 228 |
| A-2011-00292 | Information regarding the product Lakota Topical Pain Reliever - Extra Strength, NPN 02248350 by HPI Health Products Inc. - Lakota. | Disclosed in part | 25 |
| A-2011-00293 | Information regarding the product JOINT CARE ARTHROFORMULE by HPI Health Products Inc. - Lakota. | Disclosed in part | 24 |
| A-2011-00299 | AERs for the product Multaq (dronedarone). Report numbers: 000359795, 000360813, 000360816, 000360817, 000361241 and 000362723. | Disclosed in part | 6 |
| A-2011-00300 | All correspondence between Health Canada, the Parliamentary Secretary and/or other Federal Agencies related to the Common Purchasing Alliance for Drug/Pharmaceuticals and Medical Supplies/Devices. (May 1, 2010 to Jun 6, 2011). | No records exist | 0 |
| A-2011-00311 | Financial or economic modelling of the likely or assumed effects of plain packaging on the tobacco industry or tobacco manufacturers. (Jan 1, 1998 to Jun 6, 2011). | No records exist | 0 |
| A-2011-00317 | AERs for the product Lipitor (atorvastatin calcium). Report numbers: 000120830, 000137612, 000142297, 000157470 000158959, 000168305, 000168618, 000305393, 000309197, 000321172 and 000338125. | Disclosed in part | 18 |
| A-2011-00336 | A listing of the Access to Information requests submitted to Health Canada for the period of May 2011. | Disclosed in part | 25 |
| A-2011-00345 | The most up-to-date list of Drinking Water Advisories on First Nations communities across Canada. | All disclosed | 10 |
| A-2011-00351 | A copy of the report of the expert panel on energy drinks, commissioned by Health Canada. | All exempted | 0 |
| A-2011-00361 | Information regarding the product Micardis (telmisartan) by Boehringer Ingelheim Canada. | Disclosed in part | 502 |
| A-2011-00362 | AER for the product Aleve. Report number: 000363360. | Disclosed in part | 1 |
| A-2011-00364 | AERs for the product CanesOral. Report numbers: 000361844 and 000364029. | Disclosed in part | 2 |
| A-2011-00365 | AER for the product Flintstones. Report number: 000363233. | Disclosed in part | 1 |
| A-2011-00366 | AER for the product Adalat XL. Report number: 000365184. | Disclosed in part | 1 |
| A-2011-00380 | AERs for the product TECTA (pantoprazole magnesium). Report numbers: 00359327, 000359552, 000360032, 000361435 and 000362277. | Disclosed in part | 6 |
| A-2011-00425 | All callups issued under the terms of the TBIPS Standing Offer (EN578-055605) and amendments for May 2011. | No records exist | 0 |
| A-2011-00432 | All correspondence between the Canadian government and the United States of America concerning controlled narcotics in Haiti following the January 2010 earthquake in Haiti. | No records exist | 0 |
| A-2011-00434 | The Canadian submissions to the International Narcotics Board to establish the 2011 status of estimates for narcotic drug use for Canada. | No records exist | 0 |
